The research program that earned the award rests on a deceptively simple question with profound implications. Messenger RNAs, or mRNAs, are the intermediary molecules of molecular biology, ferrying genetic instructions encoded in DNA out of the cell nucleus and delivering them to ribosomes, the molecular machines that build proteins. For decades, scientists understood mRNA regulation as a story told mainly by other RNAs and by RNA-binding proteins, the classical gatekeepers that determine how stable, mobile, or productive a given mRNA molecule is. A landmark shift came in 2012, when a key study from the Jaffrey lab helped establish that mRNAs can also be regulated by the permanent attachment of chemical tags, forming reversible-looking but covalently fixed regulatory marks such as N6-methyladenosine, widely abbreviated as m6A. That epitranscriptomic layer of RNA regulation has since become one of the most vigorous areas of modern biology.

But Dr. Jaffrey and his colleagues have been pursuing a different and arguably even more elusive layer: regulation of RNA activity through transient, non-covalent interactions with ordinary cellular metabolites. Metabolites are the relatively simple molecules that participate in the cell’s metabolic processes, including amino acids, sugars, nucleotides, and their derivatives. In bacteria, metabolite-RNA interactions are well documented; structured segments of bacterial RNA called riboswitches change shape when they bind specific small molecules, allowing bacteria to tune gene expression in response to their chemical environment. For years, the assumption was that this form of regulation was a bacterial specialty. In mammalian cells, the analogous bacterial mechanism has simply not been found, despite serious and sustained searches.

That is precisely where the Jaffrey lab’s work departs from expectation. Rather than finding the bacterial recognition mechanism transplanted into human cells, the team has been accumulating evidence of interactions between metabolites and mRNAs that rely on entirely different recognition mechanisms than the ones characterized in bacteria. Dr. Jaffrey has described the situation bluntly: researchers have looked for this bacterial mechanism in mammalian cells and have not found it, yet his group has been finding evidence of metabolite-mRNA interactions that use completely different recognition principles. The implication is striking. Higher organisms may have evolved their own, previously hidden chemistry for letting metabolic state speak directly to the transcriptome, the full set of RNA molecules a cell produces.

The functional significance of these interactions may be twofold, and both possibilities carry weight. On the constructive side, Dr. Jaffrey has suggested that metabolite-mRNA interactions may act as feedback pathways through which cellular metabolism normally keeps itself within a healthy range, regulating mRNA activity in response to fluctuating metabolic conditions. In this view, the cell’s chemical state is not merely a backdrop to gene expression but an active author of it. On the pathological side, the team has observed that changes in cellular metabolism under disease conditions can alter the activity of specific mRNAs in ways that contribute to disease. If metabolic dysregulation can reroute RNA regulation toward pathological outputs, then the metabolite-RNA interface becomes a potential point of therapeutic intervention in conditions as varied as cancer and neurodegenerative disorders.

The NIH Director’s Transformative Research Award, part of the Common Fund’s High-Risk, High-Reward Research program, is designed to fund exactly this kind of intellectually adventurous science: projects that carry meaningful risk of failure but hold the potential to transform one or more fields of biomedical research if they succeed. Dr. Jaffrey and his team are unusually well positioned to attempt the leap, because they are known both for building tools for studying RNA molecules and for wielding those tools to make important discoveries. That combination of instrumentation and biological insight is critical for a project whose central challenge is detection. Metabolite binding to RNA is transient and non-covalent, making it far harder to capture than fixed chemical marks like m6A.

The new NIH-sponsored project will therefore aim to systematically catalogue and characterize metabolite-RNA interactions in human and other animal cells, moving the field from scattered observations to a comprehensive map. The Jaffrey lab plans to deploy the advanced tools it has developed for studying RNA structure to detect metabolite binding sites with high resolution, including, remarkably, within living cells. Achieving detection inside intact, functioning cells is essential, because metabolite concentrations and RNA conformations in a living cellular environment can differ dramatically from those in laboratory extracts. High-resolution mapping across human and animal cells will allow the researchers to ask whether these interactions follow recognizable rules, how abundant they are, and which biological processes they govern.

The payoff from such a map could extend well beyond basic cell biology. Most modern drugs are small-molecule drugs, but they overwhelmingly target proteins, because proteins have long offered well-defined pockets and surfaces for small molecules to grip. RNA has traditionally been viewed as an intractable drug target, lacking the druggable architecture that proteins present. If metabolites demonstrably bind RNA at specific, reproducible sites, those sites become, by definition, points where small molecules can engage RNA. Dr. Jaffrey has framed the therapeutic promise in exactly those terms, saying that as the locations where RNAs bind metabolites are clarified, the work is expected to reveal a large set of druggable sites across the transcriptome. In principle, a map of metabolite-RNA interactions could become a catalog of candidate drug targets spanning thousands of RNA molecules, opening a frontier for medicinal chemistry that complements the protein-centric pharmaceutical industry.

The breadth of the potential impact is one reason the award carries the transformative designation. Dr. Jaffrey has noted that the research could substantially change the understanding of RNA regulation, with implications for diverse areas ranging from RNA biology to cancer metabolism and neurodegeneration. Each of those fields currently treats RNA regulation and metabolism as connected but largely separate spheres; a verified, comprehensive layer of metabolite-based RNA control would force them together. Tumor cells with rewired metabolism might drive malignancy partly through metabolite-mediated changes in mRNA activity. Neurons, whose metabolism is extraordinarily demanding, might be especially vulnerable to disease-linked disruptions in this regulatory layer. As the Jaffrey lab begins its systematic mapping effort, the scientific community will be watching to see whether a hidden regulatory network, hiding in plain chemical sight inside every cell, finally comes into focus.

Subject of Research: Metabolite-mediated regulation of messenger RNA in mammalian cells

Article Title: Dr. Samie Jaffrey receives NIH Director’s Transformative Research Award

Article References: Dr. Samie Jaffrey receives NIH Director’s Transformative Research Award. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: NIH, Transformative Research Award, Samie Jaffrey, messenger RNA, RNA regulation, metabolites, m6A, Weill Cornell Medicine, RNA biology, cancer metabolism, neurodegeneration, drug targets